HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IONIS-PTP-1BRx

second-generation 2'-O-methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B,

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleotides: 15763
  - Polynucleotides: 218
    - Oligonucleotides: 5145
      - Oligodeoxyribonucleotides: 2217
        IONIS-PTP-1BRx: 1

Experts

1.	Baker, Brenda F: 1 article (01/2018)
2.	Bhanot, Sanjay: 1 article (01/2018)
3.	Digenio, Andres: 1 article (01/2018)
4.	Geary, Richard S: 1 article (01/2018)
5.	Jung, Shiangtung W: 1 article (01/2018)
6.	Morgan, Erin S: 1 article (01/2018)
7.	Pham, Nguyen C: 1 article (01/2018)
8.	Watts, Lynnetta M: 1 article (01/2018)

Related Diseases

1.	Overweight 01/01/2018 - "Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes." 01/01/2018 - "In this phase II, double-blind, randomized, placebo-controlled, multicenter trial, overweight and obese patients (BMI ≥27 kg/m2) with type 2 diabetes (HbA1c ≥7.5% [58 mmol/mol] and ≤10.5% [91 mmol/mol]) on a stable dose of metformin alone or with sulfonylurea were randomized 2:1 to IONIS-PTP-1BRx 200 mg (n = 62) or placebo (n = 30) once weekly for 26 weeks. " 01/01/2018 - "To evaluate safety and efficacy of IONIS-PTP-1BRx, a second-generation 2'-O-methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B, as add-on therapy in overweight patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea therapy. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2018 - "Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes." 01/01/2018 - "In this phase II, double-blind, randomized, placebo-controlled, multicenter trial, overweight and obese patients (BMI ≥27 kg/m2) with type 2 diabetes (HbA1c ≥7.5% [58 mmol/mol] and ≤10.5% [91 mmol/mol]) on a stable dose of metformin alone or with sulfonylurea were randomized 2:1 to IONIS-PTP-1BRx 200 mg (n = 62) or placebo (n = 30) once weekly for 26 weeks. " 01/01/2018 - "To evaluate safety and efficacy of IONIS-PTP-1BRx, a second-generation 2'-O-methoxyethyl antisense inhibitor of protein tyrosine phosphatase 1B, as add-on therapy in overweight patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea therapy. "
3.	Body Weight (Weight, Body) 01/01/2018 - "Despite both treatment groups receiving similar lifestyle counseling, mean body weight significantly decreased from baseline to week 27 with IONIS-PTP-1BRx versus placebo (-2.6 kg; P = 0.002) independent of HbA1c reduction (R2 = 0.0020). " 01/01/2018 - "Compared with placebo, IONIS-PTP-1BRx treatment for 26 weeks produced prolonged reductions in HbA1c, improved medium-term glycemic parameters, reduced leptin and increased adiponectin levels, and resulted in a distinct body weight-reducing effect."
4.	Insulin Resistance 01/01/2018 - "Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes."

Related Drugs and Biologics

1.	Non-Receptor Type 1 Protein Tyrosine Phosphatase
2.	Adiponectin
3.	Leptin
4.	Metformin (Glucophage)
5.	N 30

Related Therapies and Procedures

1.	Therapeutics